The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia

Bone Marrow Transplantation

Volumn 25, Issue 4, 2000, Pages 411-417

  Byrne, J L ^a,b,d   Stainer, C ^a   Cull, G ^a   Haynes, A P ^a,b   Bessell, E M ^a   Hale, G ^c   Waldmann, H ^c   Russell, N H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

ATG; BMT; Cell dose; GVHD; Leukaemia

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DATA ANALYSIS; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

EID: 0033996579     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702165     Document Type: Article

References (50)

1. Thomas E. Marrow transplantation tor malignant diseases. J Clin Oncol 1983; 1: 517-521.
2. Thomas E, Clift R, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
3. Goldman J, Apperley J, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med 1986; 314: 202-207.
4. Beatty P, Dahlberg S, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995; 52: 778-782.
5. Goldman J for the WMDA Executive Committee. A special report: bone marrow transplants using volunteer donors - recommendations and requirements for a standardised practice throughout the world - 1994 update. Blood 1994; 84: 2833-2839.
6. Beatty P, Ash R, Hows J, McGlave P. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centres. Bone Marrow Transplant 1985; 4: 287-290.
7. McGlave P, Beatty P, Ash R, Hows J. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728-1732.
8. Mackinnon S, Barnett L, Heller G, Or J. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia. Blood 1994; 83: 3409-3416.
9. McGlave P, Barrsch G, Anasetti C et al. Unrelated donor transplantation therapy for chronic myeloid leukemia: initial experience of the National Bone Marrow Donor Program. Blood 1993; 81: 543-550.
10. Marks D, Cullis J, Ward K et al. Allogeneic hone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 1993; 19: 207-214.
11. Hansen J, Gooley T, Martin P et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 1998; 338: 962-968.
12. Anasetti C, Hansen J. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994; 15: 221-230.
13. Davies S, Shu X, Blazar B et al. Unrelated donor bone marrow transplantation: influence of HLA-A and B incompatibility on outcome. Blood 1995; 86: 1636-1642.
14. Petersdorf E, Longton G, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
15. Sazasuki T, Takeo J, Morishima Y et al. Effect of matching class I alleles on clinical outcome after transplantation of hematopoietic cells from an unrelated donor. New Engl J Med 1998; 339: 1177-1185.
16. Hows J, Bradley B, Gore S et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-380.
17. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994; 83: 2392-2398.
18. Takenaka K, Gondo H, Yanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19: 241-248.
19. Goodrich J, Bowden R, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic bone marrow transplant. Ann Intern Med 1993; 84: 1067-1071.
20. Goodrich J, Mori M, Gleaves C et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
21. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, B and DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
22. Glucksberg H, Storb R, Fefer A. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 1974; 18: 295-304.
23. Schulman K, Sullivan KM, Weiden P. Chronic graft-versus-host disease in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Sierra J, Storer B, Hansen J et al. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia: the effect of leukaemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226-4235.
25. Clift R, Buckner C, Thomas E et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 243: 243-248.
26. Bortin M, Gale R, Kay H. Rimm A. Bone marrow transplantation for acute myelogenous leukaemia. Factors associated with early mortality. JAMA 1983; 249: 1166-1170.
27. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
28. Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes complement. Blood 1983; 62: 873-882.
29. Reisner Y, Kapoor N, Kirkpatrick D et al. Transplantation for acute leukaemia with HLA-A and B non-identical parental marrow cells fractionated with soybean agglutin and sheep red blood cells. Lancet 1981; 2: 327-330.
30. Prentice HG, Blacklock H, Janossy G et al. Use of anti-T cell monoclonal antibody OKT3v to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukaemia. Lancet 1982; 1: 700-703.
31. Prentice H, Janossy G, Price-Jones L et al. Depletion of T lymphocytes in donor marrow prevents significant graftversus-host disease in matched allogeneic leukaemic marrow recipients. Lancet 1984; 1: 472-476.
32. Waldmann H, Or R, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (CAMPATH 1). Lancet 1984; 2: 483-485.
33. Filipovich A, Vallera D, Youle R et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of lymphocytes from human bone marrow. Transplantation 1987; 44: 62-69.
34. Kernan N, Flomenberg N, Dupont B, O'Reilly R. Graft rejection in recipients of T-cell depleted HLA-identical marrow transplants for leukaemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 1987; 43: 842-846.
35. Bunjes D, Heit W, Arnold R et al. Evidence for the involvement of host-derived OKT8 positive T cells in the rejection of T-depleted HLA-identical bone marrow grafts. Transplantation 1987; 43: 501-505.
36. Apperley J, Mauro F, Goldman J et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988; 9: 239-234.
37. Hale G, Cobbold S, Waldmann H. T-cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 1988; 45: 753-757.
38. Slavin S, Or R, Naparstek E et al. New approaches for the prevention of gratt-versus-host disease in clinical bone marrow transplantation. Isr J Med Sci 1986; 22: 264-267.
39. Patterson J, Prentice H, Brenner M et al. Graft rejection following HLA-matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221-225.
40. Hale G, Zhang M-J, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
41. Cull G, Haynes AP, Byrne JL et al. Allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-Campath conditioning. Br J Haematol 2000 (in press).
42. Baurmann H, Schimmelpfennig C, Brauninger S et al. ATG as part of the conditioning in matched unrelated (MUD) BMT. Bone Marrow Transplant 1998; 21 (Suppl. 1): 336a.
43. Vitek A, Sajdova J, Hrabenek J et al. ATG reduces the risk of severe aGVHD in MUD or haploidentical BMT. Bone Marrow Transplant 1998; 21 (Suppl. 1): 406a.
44. Stockschlader M, Kruger W, Betke R et al. ATG as part of the pre-transplant conditioning regimen reduces transplant-related mortality in CML patients undergoing allogeneic transplantation. Exp Hematol 1996; 24: 679a.
45. Lanino E, Locatelli F, Porta C et al. Pre-transplant ATG vs Campath IG for GVHD prophylaxis in pediatric recipients of unrelated BMT. An AIEOP-GITMO retrospective analysis of 112 patients. Bone Marrow Transplant 1998; 21 (Suppl. 1): 411a.
46. Kato S, Kodera Y, Nagao T et al. Effect of ATG in conditioning for unrelated BMT on GVHD prophylaxis. A preliminary report of prospective cooperative study in Japan. Exp Haematol 1996; 24: 655a.
47. Holler E, Ledderose G, Knabe H et al. ATG serotherapy during pre-transplant conditioning in unrelated donor BMT: dose-dependent modulation of GVHD. Bone Marrow Transplant 1998; 21 (Suppl. 1): 105a.
48. Estey E, Plunkett W, Ghandi V et al. Fludarahine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphnoma 1993; 9: 343-350.
49. Hale G, Swirsky D, Waldmann H, Chan L. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol 1985; 60: 41-48.
50. Russell NH, Warwick R, Goldman J. Peripheral blood stem cells from unrelated donors for allogeneic transplantation. Transplantation 1999; 67: 339-340.